Vericiguat in Patients with Heart Failure and Reduced Ejection Fraction
Open accessThe DOI matches its Crossref record; 17 of the 17 references it cites were found in a registry or an index.
Abstract
BACKGROUND: The effect of vericiguat, a novel oral soluble guanylate cyclase stimulator, in patients with heart failure and reduced ejection fraction who had recently been hospitalized or had received intravenous diuretic therapy is unclear. METHODS: In this phase 3, randomized, double-blind, placebo-controlled trial, we assigned 5 050 patients with chronic heart failure (New York Heart Association class II, III, or IV) and an ejection fraction of less than 45% to receive vericiguat (target dose 10 mg once daily) or placebo, in addition to guideline-based medical therapy.The primary outcome was a composite of death from cardiovascular causes or first hospitalization for heart failure. RESULTS: Over a median of 10.8 months, a primary-outcome event occurred in 897 of 2 526 patients (35.5%) in the vericiguat group and in 972 of 2 524 patients (38.5%) in the placebo group (p = 0.02). A total of 691 patients (27.4%) in the vericiguat group and 747 patients (29.6%) in the placebo group were hospitalized for heart failure. Death from cardiovascular causes occurred in 414 patients (16.4%) in the vericiguat group and in 441 patients (17.5%) in the placebo group. The composite endpoint of death from any cause or hospitalization for heart failure occurred in 957 patients (37.9%) in the vericiguat group and in 1 032 patients (40.9%) in the placebo group (p = 0.02). Symptomatic hypotension occurred in 9.1% of the patients in the vericiguat group and in 7.9% of the patients in the placebo group (p = 0.12), syncope occurred in 4.0% of the patients in the vericiguat group and in 3.5% of the patients in the placebo group (p = 0.30). CONCLUSION: Among patients with high-risk heart failure, the incidence of death from cardiovascular causes or hospitalization for heart failure was lower among those who received vericiguat than those who received placebo.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“From a safety perspective, there was more hypotension in the vericiguat group but this did not contribute to renal dysfunction, despite the relatively low eGFR cutoff for enrollment.”
From CCS/CHFS Heart Failure Guidelines Update: Defining a New Pharmacologic Standard of Care for Heart Failure With Reduced Ejection Fraction (2021) · cites this paper as [71]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Of note, the secondary end point of total HHF was also decreased in the vericiguat group (HR, 0.91 [95% CI 0.84-0.99]; P = 0.023).”
From CCS/CHFS Heart Failure Guidelines Update: Defining a New Pharmacologic Standard of Care for Heart Failure With Reduced Ejection Fraction (2021) · cites this paper as [71]
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“The primary combined end point of CV death or first HHF was significantly lower (HR, 0.90 [95% CI 0.82-0.98]; P = 0.019) in the vericiguat group and this was driven primarily by a reduction in hospitalization rather than CV death.”
From CCS/CHFS Heart Failure Guidelines Update: Defining a New Pharmacologic Standard of Care for Heart Failure With Reduced Ejection Fraction (2021) · cites this paper as [71]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Heart Disease and Stroke Statistics—2019 Update: A Report From the American Heart Association
Benjamin, E. J., Muntner, P., Alonso, A., Bittencourt, M. S., Callaway, C. W., Carson, A. P., Chamberlain, A. M., Chang, A. R., Cheng, S., Das, S. R., et al. (2019) · Circulation · doi:10.1161/cir.0000000000000659 · Cited by 9,036
Dapagliflozin in Patients with Heart Failure and Reduced Ejection Fraction
McMurray, J. J. V., Solomon, S. D., Inzucchi, S. E., Køber, L., Kosiborod, M. N., Martinez, F. A., Ponikowski, P., Sabatine, M. S., Anand, I. S., Bělohlávek, J., et al. (2019) · New England Journal of Medicine · doi:10.1056/nejmoa1911303 · Cited by 7,140
Self-citationAngiotensin-neprilysin inhibition versus enalapril in heart failure
McMurray, J. J. V., Packer, M., Desai, A. S., Gong, J., Lefkowitz, M. P., Rizkala, A. R., Rouleau, J. L., Shi, V. C., Solomon, S. D., Swedberg, K., et al. (2014) · New England Journal of Medicine · doi:10.1056/nejmoa1409077 · Cited by 6,957
Cox’s regression model for counting processes: A large sample study
Andersen, P. K., & Gill, R. D. (1982) · The Annals of Statistics · doi:10.1214/aos/1176345976 · Cited by 4,419
Heidenreich, P. A., Albert, N. M., Allen, L. A., Bluemke, D. A., Butler, J., Fonarow, G. C., Ikonomidis, J. S., Khavjou, O., Konstam, M. A., Maddox, T. M., et al. (2013) · Circulation: Heart Failure · doi:10.1161/hhf.0b013e318291329a · Cited by 2,804
Self-citationSoluble Guanylate Cyclase as an Emerging Therapeutic Target in Cardiopulmonary Disease
Stasch, J.-P., Pacher, P., & Evgenov, O. V. (2011) · Circulation · doi:10.1161/circulationaha.110.981738 · Cited by 601
Ruppar, T. M., Cooper, P. S., Mehr, D. R., Delgado, J. M., & Dunbar‐Jacob, J. M. (2016) · Journal of the American Heart Association · doi:10.1161/jaha.115.002606 · Cited by 415
Gheorghiade, M., Greene, S. J., Butler, J., Filippatos, G., Lam, C. S. P., Maggioni, A. P., Ponikowski, P., Shah, S. J., Solomon, S. D., Kraigher-Krainer, E., et al. (2015) · JAMA · doi:10.1001/jama.2015.15734 · Cited by 397
Self-citationClinical Course of Patients With Worsening Heart Failure With Reduced Ejection Fraction
Butler, J., Yang, M., Manzi, M. A., Hess, G. P., Patel, M. J., Rhodes, T., & Givertz, M. M. (2019) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2018.11.049 · Cited by 245
Self-citationArmstrong, P. W., Roessig, L., Patel, M. J., Anstrom, K. J., Butler, J., Voors, A. A., Lam, C. S. P., Ponikowski, P., Temple, T., Pieske, B., et al. (2018) · JACC: Heart Failure · doi:10.1016/j.jchf.2017.08.013 · Cited by 208
Self-citation
Cited by
Items 901–1,000 of 1,000
Gándara-Ricardo, J. A., Muñoz-Ortiz, E., Aguilar-Molina, O. E., García-Rueda, K. A., Giraldo-Ramírez, S., Salamanca, J. F., & Sénior, J. M. (2021) · Acta Médica Colombiana · doi:10.36104/amc.2021.2108 · Cited by 1
Anti-Remodeling Cardiac Therapy in Patients With Duchenne Muscular Dystrophy, Meta-Analysis Study
Raccah, B. H., Biton, B., Amir, O., Gotsman, I., Nahman, D., & Matok, I. (2022) · Frontiers in Pharmacology · doi:10.3389/fphar.2021.769896 · Cited by 3
“Soluble guanylate-cyclase inhibitors and myosin activators led to significant, yet less impressive results (Armstrong et al., 2020; Teerlink et al., 2021).”
ResultCHRONIC HEART FAILURE: VIEW OF THE CONTEMPORARY DEFINITION AND CLASSIFICATION
Bubeshka, D. A., & Snezhitskiy, V. А. (2021) · Journal of the Grodno State Medical University · doi:10.25298/2221-8785-2021-19-6-696-702 · Cited by 1
Carbohydrate antigen 125 in heart failure: congestive kidneys or beyond?
Higgins, A. R., & Tang, W. H. W. (2021) · European Heart Journal Acute Cardiovascular Care · doi:10.1093/ehjacc/zuab027 · Cited by 2
Stawiarski, K. M., & Ramakrishna, H. (2022) · Journal of Cardiothoracic and Vascular Anesthesia · doi:10.1053/j.jvca.2022.02.023 · Cited by 2
Follmann, M., Becker, C., Roessig, L., Sandner, P., & Stasch, J. (2022) · Wiley eBooks · doi:10.1002/9781119627784.ch3 · Cited by 2
Self-citationNakata, T., Shindo, T., Ito, K., Eguchi, K., Monma, Y., Ichijo, S., Ryoke, R., Satoh, W., Kumasaka, K., Sato, H., et al. (2022) · SSRN Electronic Journal · doi:10.2139/ssrn.4050029 · Cited by 2
Ischemic Mitral Regurgitation: The Role of Transcatheter Edge-to-Edge Repair Using the MitraClip
Saji, M., Izumi, Y., Higuchi, R., Kitamura, M., Takamisawa, I., Nanasato, M., Shimokawa, T., & Isobe, M. (2022) · Journal of Coronary Artery Disease · doi:10.7793/jcad.28.002 · Cited by 2
Alzate, J. A., Rajendran, P. S., & Gaggin, H. K. (2022) · Circulation Heart Failure · doi:10.1161/circheartfailure.122.010156 · Cited by 2
Next-Level Natriuretic Peptide Measurement
Nersting, J., Terzic, D., Hansen, L. H., & Goetze, J. P. (2023) · Clinical Chemistry · doi:10.1093/clinchem/hvad013 · Cited by 2
Leveraging Biomarkers for Precision Medicine in Heart Failure
Grossman, S. R., & Gaggin, H. K. (2023) · Journal of Cardiac Failure · doi:10.1016/j.cardfail.2023.03.001 · Cited by 4
Störk, S. (2025) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2025.09.021 · Cited by 2
Docherty, K. F., & McMurray, J. J. V. (2025) · JACC Heart Failure · doi:10.1016/j.jchf.2025.102763 · Cited by 2
Gilyarevsky, S. R., & VIu, M. (2023) · Russian Journal of Cardiology · doi:10.15829/1560-4071-2023-5422 · Cited by 1
Short-term study of atrial shunt and improvement of functional mitral regurgitation
Shang, X., Liu, M., Zhong, Y., Wang, X., Chen, S., Fu, X., Sun, M., Li, G., Xie, M., Song, G., et al. (2023) · Journal of Cardiothoracic Surgery · doi:10.1186/s13019-023-02398-9 · Cited by 1
“The diagnostic criteria for HFrEF [22] encompassed the following parameters: (1) patients aged over 18 years; (2) Individuals with chronic heart failure categorized as New York Heart Association [NYHA] function class II, III, or IV; (3) patients displaying a left ventricular ejection fraction…”
MethodHocutt, B., Owen, M. I., & Albert, N. M. (2024) · The Journal for Nurse Practitioners · doi:10.1016/j.nurpra.2024.105088 · Cited by 1
Lazareva, L., Shubrook, J. H., & Dhond, M. R. (2024) · Journal of Osteopathic Medicine · doi:10.1515/jom-2024-0071 · Cited by 2
Shakthivel, C. D. (2024) · Advances in medical technologies and clinical practice book series · doi:10.4018/979-8-3693-2703-6.ch005 · Cited by 2
The Role of Vericiguat in Early Phases of Anterior Myocardial Infarction: A Potential Game-Changer?
Cacciapuoti, F., Mauro, C., Capone, V., Chianese, S., Tarquinio, L. G., Gottilla, R., Marsico, F., Crispo, S., & Cacciapuoti, F. (2024) · Medicina · doi:10.3390/medicina60101595 · Cited by 2
“The VICTORIA trial highlighted vericiguat’s role in improving outcomes for patients with HFrEF [10], making it a compelling candidate for use in acute anterior MI.”
BackgroundMata, E., Garcia, B. L., Tinoco, M. G., Castro, M., Pinheiro, L., Português, J., Ferreira, F. C., Ribeiro, S., Melica, B., & Lourenço, A. (2025) · Monaldi Archives for Chest Disease · doi:10.4081/monaldi.2025.3264 · Cited by 1
SGLT‐2 inhibitors for cardiac amyloidosis: Hype or hope?
Tangianu, F., Nicolini, E., Dentali, F., & Bonaventura, A. (2025) · European Journal of Clinical Investigation · doi:10.1111/eci.70063 · Cited by 1
“19 Based on its mechanism of action, vericiguat improves the regulation of the vascular tone and similarly to SGLT-2 inhibitors might be considered in CA patients with reduced LVEF.”
Nitric oxide based therapies for peripheral artery disease: Evidence and opportunities
McDermott, M. M., Kim‐Shapiro, D. B., & Allen, J. D. (2025) · Nitric Oxide · doi:10.1016/j.niox.2025.05.002 · Cited by 1
Pulmonary Hypertension in Left Heart Disease and Chronic Right Ventricular Failure
Watson, H., Patel, B., & Caccamo, M. A. (2025) · Medical Clinics of North America · doi:10.1016/j.mcna.2025.03.010 · Cited by 1
Montinari, M. R., Minelli, S., Horowitz, J. D., & Caterina, R. D. (2025) · Vascular Pharmacology · doi:10.1016/j.vph.2025.107517 · Cited by 3
Diagnose und Therapie der Herzinsuffizienz mit reduzierter Ejektionsfraktion
Soltani, S., & Bauersachs, J. K. (2025) · Herz · doi:10.1007/s00059-025-05324-y · Cited by 1
Sciatti, E., Odoardo, L. A. F. D., Zucchetti, O., Senni, M., & D’Elia, E. (2025) · Heart · doi:10.1136/heartjnl-2025-326009 · Cited by 1
Kayhan, Y., Kaya, H., Kavalcı, V., Abuş, S., Bıyıklı, K., Markirt, S., Can, C., Markirt, E., & Özdemir, D. M. (2025) · Annals of Noninvasive Electrocardiology · doi:10.1111/anec.70101 · Cited by 1
O’Connor, C. M., Rathwell, S., Mehrotra, D. V., Corda, S., McMullan, C. J., Lam, C. S. P., Ezekowitz, J. A., Piekse, B., Hernandez, A. F., Anstrom, K. J., et al. (2025) · Journal of Cardiac Failure · doi:10.1016/j.cardfail.2025.07.024 · Cited by 2
Self-citationWesterhout, C. M., Alemayehu, W. G., Solal, A. C., Lam, C. S. P., Ezekowitz, J. A., Corda, S., McMullan, C. J., O’Connor, C. M., Armstrong, P. W., & for the VICTORIA Study Group (2025) · ESC Heart Failure · doi:10.1002/ehf2.15416 · Cited by 1
Self-citationMolecular Aspects of Soluble Guanylate Cyclase Activation and Stimulator Function
Houghton, K. A., Thomas, W. C., & Marletta, M. A. (2025) · Biochemistry · doi:10.1021/acs.biochem.5c00424 · Cited by 1
Emerging Research and Innovations in Heart Failure
Yang, Z., Luo, D., & Zhang, C. (2025) · Cardiology Discovery · doi:10.1097/cd9.0000000000000176 · Cited by 1
Safaee, A., Kheirandish, R., Rajizadeh, M. A., Rezaei, M. H., Madadizadeh, E., Bagheri, M., Majidpour, F., Bashiri, H., & Khoramipour, K. (2025) · Naunyn-Schmiedeberg s Archives of Pharmacology · doi:10.1007/s00210-025-04688-6 · Cited by 3
Cannata, A. N., & Packer, M. (2025) · European Heart Journal · doi:10.1093/eurheartj/ehaf888 · Cited by 1
The changing landscape of heart failure: translating management into the modern era
Madaudo, C., Ibrahim, W., Noakes, D., Bromage, D. I., Sinagra, G., McDonagh, T., & Cannata, A. N. (2025) · European Journal of Internal Medicine · doi:10.1016/j.ejim.2025.106633 · Cited by 1
Maestre-Luque, L. C., Manzanares, R. G., Hidalgo, F., de Lezo, J. S., Romero, M., Gutiérrez, A., Gallo, I., Herrera, C., Espejo-Pérez, S., Fernández-López, O., et al. (2025) · Stem Cell Research & Therapy · doi:10.1186/s13287-025-04854-w · Cited by 1
“As reported in other RCTs in patients with cardiovascular disease, enrichment criteria to select high-risk patients can either enhance the chance of improvement [18–20] or, conversely, limit the effect size of the therapy [21].”
Abdullakutty, J., Abhyankar, A. D., Seth, S., Sharma, K. H., Aggarwal, R. K., Bhalani, N. C., Vijan, V., Bansal, S., Jain, R. K. P., Banerjee, S., et al. (2025) · Cardiology and Therapy · doi:10.1007/s40119-025-00442-4 · Cited by 1
Inoue, T., Takahama, H., Suzuki, H., Arai, M., Kikuchi, N., Satoh, T., Yaoita, N., Yamamoto, S., Nochioka, K., Nakano, M., et al. (2026) · IJC Heart & Vasculature · doi:10.1016/j.ijcha.2025.101863 · Cited by 1
“Taken together with the VICTORIA trial [15] results showing a modest reduction in mortality and morbidity with vericiguat in patients with chronic HFrEF, the present findings offer mechanistic insights that align with the clinical effects reported in these high-risk cohorts.”
InfluentialAdvances in Diagnosis and Treatment of Acute and Chronic Heart Failure: A Comprehensive Review
Kenyon, C. R., Wyk, L. V., Flom, A. P., Ibrahim, R., Pham, H. N., Lakhdar, S., Iftikhar, M., & Abdelnabi, M. (2026) · Journal of Clinical Medicine · doi:10.3390/jcm15020618 · Cited by 4
“In the VICTORIA trial, vericiguat reduced the composite endpoint of cardiovascular death or first heart failure hospitalization by 10% in high-risk HFrEF patients with recent clinical worsening [152].”
Greene, S. J., Michel, A., Lecomte, C., Manca, P., Holl, K., & Senni, M. (2026) · American Heart Journal Plus Cardiology Research and Practice · doi:10.1016/j.ahjo.2026.100721 · Cited by 1
“The SOCRATES-REDUCED trial [9] suggested a dose-response relationship between increasing vericiguat dose and NT-proBNP reduction, and in the VICTORIA trial [10], 10 mg/day was the effective target dose tested.”
Zhong, W., Jiang, F., Wang, H., Yin, X., Zhang, B., Cui, H. L., & Zhou, J. (2026) · BMC Geriatrics · doi:10.1186/s12877-025-06948-9 · Cited by 1
Endothelin-1 in the failing Fontan: pathobiology, precision therapeutics, and future trial design
Maiza, I. (2026) · Frontiers in Pediatrics · doi:10.3389/fped.2025.1718057 · Cited by 1
Kang, S. H., Park, S. Y., Lim, Y. J., Kim, B. Y., & Do, J. Y. (2026) · Renal Failure · doi:10.1080/0886022x.2026.2620166 · Cited by 1
Shi, X., Zhao, A., Ding, Y., Gu, L., Yang, T., Wang, H., Wang, Q., Wang, S., & Wang, L. (2026) · BMC Cardiovascular Disorders · doi:10.1186/s12872-026-05622-1 · Cited by 1
“Furthermore, although the VICTORIA trial confirmed that vericiguat significantly reduced the risk of the primary composite endpoint (CVD or first HHF) in HFrEF patients (HR 0.90 [95% CI 0.82–0.98]; P = 0.02), the use of ARNI and SGLT2 inhibitors was relatively limited in the VICTORIA trial [13, 21].”
InfluentialPagel, P. S., Hang, D., Freed, J. K., & Crystal, G. J. (2026) · Journal of Cardiothoracic and Vascular Anesthesia · doi:10.1053/j.jvca.2026.02.035 · Cited by 2
Sideris, K., Bunsawat, K., Brinker, L. M., Braun, E., Iacovelli, J. J., Chen, A., Simmons, J. M., Zhao, J., Carter, S., Tseliou, E., et al. (2026) · The American Journal of Cardiology · doi:10.1016/j.amjcard.2026.02.062 · Cited by 1
Nicholls, H., Vargas, J. D., Sanghvi, M. M., Ahn, H., Chahal, C. A. A., Khanji, M. Y., Petersen, S. E., Munroe, P. B., & Aung, N. (2026) · Nature Communications · doi:10.1038/s41467-026-69982-0 · Cited by 4
“Recent HF therapeutic research diverges from the conventional neurohormonal axis to newer pathways such as renal glucose excretion (sodium glucose cotransporter 2 inhibitors), nitric oxide synthase-guanylate cyclase system (Vericiguat), and myocardial contractility (Omecamtiv Mecarbil) 10 .”
Medeiros, S. G. F., Guimarães, R. D. C. A., Inada, A. C., Fernandes, C. D. P., Ferreira, R. D. S., Freitas, K. D. C., Donadon, J. R., do Nascimento, V. A., & Hiane, P. A. (2026) · Antioxidants · doi:10.3390/antiox15030322 · Cited by 2
“In parallel, emerging therapies, including soluble guanylate cyclase stimulators such as vericiguat, GLP-1 receptor agonists, and glucagon receptor blockers, have the potential to reduce myocardial stiffness, particularly in inflammatory or metabolically compromised phenotypes [61,62].”
Zhao, Y., Li, H., Wu, Z., Yin, Y., Wang, H., Zhang, L., Zhang, Y., Jiang, B., 蒋廷波, & Li, H. (2026) · The FASEB Journal · doi:10.1096/fj.202501845rrr · Cited by 1
“Vericiguat (VIT) is a new oral stimulator of soluble guanylate cyclase (sGC) that was recently approved for treating chronic heart failure [14, 15].”
Wang, Y., Xu, F., Song, C., Wang, X., Zhou, H., Qu, T., Li, H., Luo, Q., Lei, W., Yin, Y., et al. (2026) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-026-02624-5 · Cited by 2
“…heart failure with reduced ejection fraction (HFrEF) without increasing the risk of hypotension/syncope, which is a crucial safety advantage for AS. 27,30 Our previous in vitro studies revealed the superior anti-calci fi c ef fi cacy of vericiguat compared with BNP and sildena fi l in OM-induced…”
InfluentialWang, D., Xu, X., Lu, J., Gao, J., Li, Y., Pan, G., & Peng, W. (2026) · Frontiers in Cardiovascular Medicine · doi:10.3389/fcvm.2026.1746467 · Cited by 2
Takeichi, M., Kohsaka, S., Nochioka, K., Ohlmeier, C., Michel, A., Holl, K., Yamamoto, H., Arita, Y., Kim, S. W., & Okami, S. (2026) · IJC Heart & Vasculature · doi:10.1016/j.ijcha.2026.101900 · Cited by 1
“The findings of the present study demonstrated that, in real-world clinical practice, vericiguat is administered to a broader patient population than that included in the VICTORIA trial [6,8,20].”
InfluentialSatoh, T., Sugimura, K., Fukumoto, Y., Abe, K., Dohi, Y., Dohi, K. D., Taniguchi, Y., Hashimoto, A., Kato, S., Nakamura, K., et al. (2026) · Journal of the American Heart Association · doi:10.1161/jaha.125.045155 · Cited by 1
“Although vericiguat has been reported to improve RV–PA coupling, 21,22 the limited number of treated patients in this study precluded a detailed analysis.”
Correale, M., Santagata, F., D’Alessandro, D., Capasso, R., Tesse, M., Barile, M., Furore, A., Carbonara, M., Mazzeo, P., Dattilo, G., et al. (2026) · Journal of Cardiovascular Medicine · doi:10.2459/jcm.0000000000001858 · Cited by 2
The effect of vericiguat on sudden cardiac death: insights from the VICTOR trial
Fioretti, F., Zannad, F. M., Barash, I., Corda, S., Ezekowitz, J. A., Lam, C. S. P., Mentz, R. J., O’Connor, C. M., Bayh, I., Xing, A., et al. (2026) · European Journal of Heart Failure · doi:10.1093/ejhf/xuag049 · Cited by 1
Self-citationKanenawa, K., Andò, K., Nasu, T., Fujimoto, W., Kagiyama, N., Shiraishi, Y., Ishii, S., Ijichi, T., Nakazawa, G., Kanaoka, K., et al. (2026) · Circulation Journal · doi:10.1253/circj.cj-25-1087 · Cited by 1
Emerging therapeutic directions for inotropic therapy in heart failure
Pironti, G., Maack, C., Andersson, D. C., & Lund, L. H. (2026) · Med · doi:10.1016/j.medj.2026.101073 · Cited by 3
Sardu, C., D’Onofrio, N., Fumagalli, C., Balestrieri, M. L., Landolfi, A., Marca, C. L., Giordano, V., Donisi, I., Rambaldi, P., Gatta, G., et al. (2026) · JACC Advances · doi:10.1016/j.jacadv.2026.102708 · Cited by 1
Li, D., Dong, Y., Yao, L., Chen, X., Li, Y., Deng, X., Li, J., Wang, M., & Fu, D. (2026) · Cardiovascular Toxicology · doi:10.1007/s12012-026-10115-w · Cited by 1
Ruíz, M. G., Girón, M. F. D. S., Groba-Marco, M. D. V., Jorge, L. R., Saavedra, C. P., Bou, E. M., Guerra, R. A., Benitez, M. A. S., Bujanda, M. A., Ramirez, L. B., et al. (2026) · Cardiac failure review · doi:10.15420/cfr.2025.45 · Cited by 1
“These results are in line with those of the VICTORIA trial, in which patients with higher NT-proBNP levels benefited less from vericiguat, suggesting that vericiguat should be started as soon as possible and that prescription should not be delayed until advanced stages of HF. 6,9,34,35 Our findings showed that in clin…”
InfluentialNamba, H. F., de Jong, E. A. M., Boerhout, C. K. M., Mechroubi, A., Nijkamp, T., Damman, P., Dimitriu‐Leen, A. C., Meuwissen, M., Heestermans, A., den Haan, M. C., et al. (2026) · American Heart Journal · doi:10.1016/j.ahj.2026.107451 · Cited by 1
Wen, S., Wang, C., Xu, Z., Chen, L., He, Y., Ren, Y., Yuan, Y., Li, Y., Dong, M., Gong, M., et al. (2026) · Cardiovascular Diabetology · doi:10.1186/s12933-026-03164-6 · Cited by 1
“The VICTORIA trial (2020) demonstrated a 10% reduction in the composite of CV death and first HF hospitalization (HR 0.90, 95% CI 0.82–0.98, p = 0.019) among high-risk patients with HFrEF and recent decompensation [83].”
InfluentialPawłowska, I., Kuźbicka, K., Kowalczys, A., Pawłowski, L., & Kocić, I. (2026) · Frontiers in Pharmacology · doi:10.3389/fphar.2026.1786007 · Cited by 1
“Vericiguat has been shown to reduce cardiovascular death or hospitalization in patients with heart failure with reduced ejection fraction (HFrEF) and may be considered in those who remain symptomatic despite guideline-directed therapy (Armstrong et al., 2020; McDonagh et al., 2022).”
Use of soluble guanylyl cyclase stimulators in heart failure therapy—a mode of action perspective
Ruschitzka, F., Łukowski, R., Corda, S., Meier, C., & Sandner, P. (2026) · ESC Heart Failure · doi:10.1093/eschf/xvag117 · Cited by 1
“146,148 A third trial, VICTOR, was conducted to extend the available data on the efficacy and tolerability of vericiguat to patients with HF without a recent worsening/decompensation event ( Table 1 ).”
Skouri, H. N., Abdin, A., Müllens, W., Bucciarelli‐Ducci, C., Starling, R. C., van der Meer, P., Savarese, G., Gal, T. B., Bayés‐Genís, A., Heymans, S. R. B., et al. (2026) · ESC Heart Failure · doi:10.1093/eschf/xvag115 · Cited by 4
Hao, Q.-Y., Zeng, Y.-H., Zhan, Z.-B., Liu, X., Guo, J., Bai, K., Weng, J., Gao, J., & Li, Z. (2026) · Journal of the American Heart Association · doi:10.1161/jaha.125.046542 · Cited by 1
“11 18 More important, activated NO- cGMP-PKG signaling is recently reported to maintain VSMC contractile phenotype and vascular tone, it is plausible that vericiguat may exert protective effects against VC through modulation of this pathway.”
Alnuaimi, N. S., Lößlein, L., Mousa, M., Khader, T. A., Alkhaaldi, A., Azzam, S. K., Craenenbroeck, A. H. V., Ashraf, S. M., Carmeliet, P., & AlSafar, H. S. (2026) · Cardiovascular Diabetology · doi:10.1186/s12933-026-03187-z · Cited by 1
Efficacy and Safety of Vericiguat in Heart Failure: A Systematic Review and Meta-Analysis
Kilic, A., Saxena, A., Khan, B., Rupanshu, R., Mann, R. S., & Chopra, I. (2026) · Cureus · doi:10.7759/cureus.108653 · Cited by 1
“In the HFrEF subgroup, which included 11,611 patients from the Armstrong et al. [12], Butler et al. [13], and Gheorghiade et al. [19] trials, vericiguat was associated with a significant reduction in the composite endpoint of cardiovascular death or HF hospitalization compared with placebo (RR…”
InfluentialOne-year multicenter prospective real-world study of vericiguat effectiveness and safety in Spain
Esteban‐Fernández, A., Bernal, B. C., López‐Vilella, R., de Lara, G., Tornero, L. C. B., Barrantes-Castillo, M., Otero, I. G., Villota, J. N., Robles‐Gamboa, C., López-Aguilera, J., et al. (2026) · ESC Heart Failure · doi:10.1093/eschf/xvag138 · Cited by 1
“12 25 This study (VERISEC) aimed to describe the clinical profile of patients initiating vericiguat, assess GDMT optimization, and evaluate safety and clinical outcomes during a 12-month follow-up.”
InfluentialLeptin in Obesity‐Related Heart Failure: Pathophysiological Mechanisms and Therapeutic Implications
Li, X., Wang, W., Zhang, Y., Ding, P., & Li, X. (2026) · Comprehensive physiology · doi:10.1002/cph4.70189 · Cited by 2
Li, S., Sun, Y., Lai, Y., Wang, H. Z., Han, J., Zhang, Y., Gao, M., Wang, J., Zhang, J., Liu, H. L., et al. (2026) · JAMA Network Open · doi:10.1001/jamanetworkopen.2026.20145 · Cited by 1
Raghavan, S., Brockunier, L. L., Guo, J., Rosauer, K. G., Smith, C., Yang, Q., Shepherd, C., Yang, L., Pai, L.-Y., Metzger, J., et al. (2026) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2026.130724 · Cited by 1
Mariani, M. V., D’Amato, A., Palombi, M., Segato, C., Recchioni, T., Bruti, R. M., Trivigno, S., Myftari, V., Germanò, R., Giorgio, E. D., et al. (2026) · Heart Rhythm · doi:10.1016/j.hrthm.2026.06.057 · Cited by 1
Laborante, R., Bianchini, E., Beer, B. N., Valente, V., Mavridis, D., Bidino, R. D., D’Amario, D., Roes, K. C. B., Mol, P. G. M., Basile, C., et al. (2026) · European Journal of Heart Failure · doi:10.1093/ejhf/xuag233 · Cited by 2
Self-citationFazzini, L., Milenkovic, S., Sciatti, E., Moretti, I., Guida, L., Dessalvi, C. C., Senni, M., Perlini, S., & D’Elia, E. (2026) · International Journal of Cardiology · doi:10.1016/j.ijcard.2026.134684 · Cited by 1
Gigante, A., Cusumano, G., D’Amato, A., Segato, C., Germanò, R., Brigato, C., Cascone, R., Giovagnoli, F., Myftari, V., Cianci, R., et al. (2026) · International Journal of Cardiology · doi:10.1016/j.ijcard.2026.134682 · Cited by 1
Vericiguat for the Treatment of Coronary Vasospasm (ViVA)
Namba, H. F., de Jong, E. A. M., Dimitriu‐Leen, A. C., Meuwissen, M., Heestermans, T. A. C. M., den Haan, M. C., Beijk, M. A. M., Vos, N. S., Boerhout, C. K. M., Mechroubi, A., et al. (2026) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2026.08.037 · Cited by 1
Management of chronic heart failure
Osmanska, J., & Gardner, R. S. (2020) · Clinics in Integrated Care · doi:10.1016/j.intcar.2020.100016 · Cited by 1
Sequential design and analysis in the randomized clinical trial: A historical perspective
Rosenberger, W. F. (2020) · Sequential Analysis · doi:10.1080/07474946.2020.1823190 · Cited by 1
Neue Therapiekonzepte für die Herzinsuffizienz: Studien-Highlights 2020
Birner, C. M., Laufs, U., & Frey, N. (2021) · Der Kardiologe · doi:10.1007/s12181-021-00446-z · Cited by 1
Vericiguat—A New Addition for Heart Failure With Reduced Ejection Fraction
Harrington, D. H., & Lenahan, C. M. (2021) · The Journal for Nurse Practitioners · doi:10.1016/j.nurpra.2021.07.010 · Cited by 1
Gan, H., Tang, H. Y., Huang, Y., Wang, D., Pu, P., & Zuo, Z. (2021) · Reviews in Cardiovascular Medicine · doi:10.31083/j.rcm2203069 · Cited by 1
Innovationen in der medikamentösen Therapie der Herzinsuffizienz
Abdin, A., & Böhm, M. (2021) · CardioVasc · doi:10.1007/s15027-021-3544-y · Cited by 1
“Als solcher stimuliert er direkt die Bildung von Stickstoffmonoxid (NO), sensibilisiert aber auch die aktivierende Wirkung von endogener Stimulation der NO-Synthase [26].”
BackgroundInfluentialKain, V., & Halade, G. V. (2021) · Molecular and Cellular Endocrinology · doi:10.1016/j.mce.2021.111521 · Cited by 1
de Oliveira, M. T., Barretto, A. C. P., Carlo, C. H. D., Jallad, S., & Chaud, M. S. D. A. (2022) · ABC Heart Failure & Cardiomyopathy · doi:10.36660/abchf.20220009 · Cited by 3
“The Global Study in Subjects with Heart Failure with Reduced Ejection Fraction (VICTORIA), 11 efficacy and safety of vericiguat in patients with reduced EF and chronic HF with recent decompensation.”
MethodImplementation of Multiple Evidence-Based Heart Failure Therapies
Latif, A., Ahsan, M. J., Lateef, N., Kapoor, V., Tran, A. M., Abusnina, W. A., Lundgren, S. W., Goldsweig, A. M., Ahsan, M. Z., & Mirza, M. M. (2022) · Current Problems in Cardiology · doi:10.1016/j.cpcardiol.2022.101293 · Cited by 1
Málek, F., & Táborský, M. (2022) · Cor et Vasa · doi:10.33678/cor.2022.079 · Cited by 1
“Po propuštění z nemocnice lze začít podávat i vericiguat perorálně se zahajovací dávkou 2,5 mg denně.(20) Ambulantní pacient ve stabilizovaném stavu s de novo HFrEF neischemické etiologie”
Europäische Leitlinien Herzinsuffizienz: medikamentöse Therapie
Grundmann, S., & Mühlen, C. V. Z. (2023) · Herz · doi:10.1007/s00059-022-05157-z · Cited by 2
“Neu ist hier die Aufnahme von Vericiguat, einem Stimulator der löslichen Guanylatzyklase, mit einer IIbEmpfehlung für Patienten mit symptomatischer Herzinsuffizienz nach einer herzinsuffizienzbedingten Hospitalisierung, um, basierend auf der VICTORIA-Studie [7], insbesondere das Risiko für erneute Dekompensationen zu…”
BackgroundGonzález‐Juanatey, J. R., Colet, J. C., Pascual-Figal, D. A., Bayés‐Genís, A., Cepeda, J. M., García‐Pinilla, J. M., Quintana, A. G., Manzano, L., & Zamorano, J. L. (2023) · Patient Preference and Adherence · doi:10.2147/ppa.s400403 · Cited by 1
“98).(40) These results were consistent regardless of the previous use of HF treatment, renal function, or index event, and were particularly effective in those patients with NT-proBNP levels <8000 pg/mL.”
BackgroundMethodResultInfluentialKobalava, Z. D., & Назаров, И. С. (2023) · Kardiologiia · doi:10.18087/cardio.2023.3.n2418 · Cited by 1
Kühlein, T., Roos, M., Beier, M., Eggenwirth, P., Engel, B., & Scherer, M. (2023) · Zeitschrift für Allgemeinmedizin · doi:10.1007/s44266-023-00078-4 · Cited by 2
Assessing QTc Effects of Vericiguat Using Two Different Concentration-QTc Modeling Approaches
Ruehs, H., Solms, A., Frei, M., Becker, C., Trujillo, M. E., Garmann, D., & Meyer, M. C. (2023) · Clinical Pharmacokinetics · doi:10.1007/s40262-023-01282-y · Cited by 1
“5 mg (treatment A) was uptitrated to 5 mg (treatment B) and then to 10 mg (treatment C) at 14 (±3)-day intervals for a total treatment duration of 42 days, which corresponds to the dosing regimen utilized in the phase III VICTORIA study [3].”
BackgroundMethodInfluentialInvestigation of Betty Newman’s Systemic Model in a Patient With Heart Failure
Afra, L. G., Baghery, M. A. H., & Bahroodi, P. S. (2023) · Journal of Vessels and Circulation · doi:10.32598/jvc.3.2.102.2 · Cited by 1
Zhang, X., & Zhang, H. (2023) · International Journal of Drug Discovery and Pharmacology · doi:10.53941/ijddp.2023.100010 · Cited by 1
Zhao, X., Yang, A., Zheng, G., Lin, R., Xu, Y., & He, S. (2023) · Progress In Electromagnetics Research Letters · doi:10.2528/pierl23091301 · Cited by 1
Matta, A. G., Ohlmann, P., Nader, V., Levai, L., Kang, R., Carrié, D., & Roncalli, J. G. (2023) · Current Problems in Cardiology · doi:10.1016/j.cpcardiol.2023.102347 · Cited by 1
Therapie der Herzinsuffizienz mit reduzierter Pumpfunktion
Abdin, A., & Böhm, M. (2024) · DMW - Deutsche Medizinische Wochenschrift · doi:10.1055/a-2054-9636 · Cited by 1
“Die VICTORIA-Studie zeigte, dass Vericiguat bei Patienten mit HFrEF nicht zu einer signifikant höheren Inzidenz der symptomatischen Hy-potonie (9,1% gegenüber 7,9%; P=0,12) oder Synkopen (4,0% gegenüber 3,5%; P=0,30) führte, im Vergleich zu Placebo [20].”
BackgroundIs inadequate risk stratification diluting hazard ratio estimates in randomized clinical trials?
Mehrotra, D. V., & West, R. M. (2024) · Clinical Trials · doi:10.1177/17407745231222448 · Cited by 1
DESAFIOS E AVANÇOS NA ABORDAGEM DA INSUFICIÊNCIA CARDÍACA COM FRAÇÃO DE EJEÇÃO REDUZIDA
Wollmann, C. A. R., Freire, E. M., de Almeida, E. B., de Camargo, G. L., Filho, G. S. L. S., Borges, H. D. S., Ferreira, P. C. D. L., & Faria, T. M. (2024) · EPITAYA eBooks · doi:10.47879/ed.ep.2024264p603 · Cited by 2
Ikeya, Y., Okumura, Y., Kogawa, R., Nagashima, K., Nakai, T., Yokoyama, K., Iso, K., Kato, T., Tsuda, T., Tachibana, E., et al. (2024) · Journal of Arrhythmia · doi:10.1002/joa3.13028 · Cited by 1
Tang, Y. (2024) · Springer eBooks · doi:10.1007/978-981-19-7712-1_1 · Cited by 3
Metadata
- Authors
- Armstrong, P. W., Pieske, B., Anstrom, K. J., Ezekowitz, J., Hernandez, A. F., Butler, J., Lam, C. S. P., Ponikowski, P., Voors, A. A., Jia, G., McNulty, S. E., Patel, M. J., Roessig, L., Koglin, J., & O’Connor, C. M.
- Affiliations
- University of Alberta (CA)
- Merck & Co., Inc., Rahway, NJ, USA (United States) (US)
- Inova Health System (US)
- ORCID
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2020-05-14
- Volume
- 382
- Issue
- 20
- Pages
- 1883-1893
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W3013207865
- Semantic Scholar
- f98a684f8b44644864e75febeca130b492e75a2c
- Cited by
- 1,358
- References
- 17
- Citations by year
- 2026: 170 · 2025: 213 · 2024: 189 · 2023: 253 · 2022: 225 · 2021: 207 · 2020: 96
- FWCI
- 121.19
- Type
- journal article
- Language
- en
- Open access
- hybrid
- doi.org
- Licence
- Locations
- New England Journal of Medicine (publishedVersion, other-oa)
- PubMed (publishedVersion)
- Zurich Open Repository and Archive (University of Zurich) (acceptedVersion, other-oa)
- HAL (submittedVersion)
- Institutional Research Information System (Università degli Studi di Brescia) (submittedVersion)
- University of Groningen research database (University of Groningen / Centre for Information Technology) (submittedVersion, other-oa)
- Zurich Open Repository and Archive (University of Zurich) (submittedVersion, other-oa)
- Zurich Open Repository and Archive (University of Zurich)
- Funders
- Bayer
- Merck
- Topics
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Heart Failure Treatment and Management
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Cardiovascular Function and Risk Factors
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Heart rate and cardiovascular health
- Keywords
- vericiguat, heart failure with reduced ejection fraction, soluble guanylate cyclase stimulator, cardiovascular mortality, heart failure hospitalization, symptomatic hypotension, syncope, chronic heart failure
- MeSH terms
- Soluble Guanylyl Cyclase, Administration, Oral, Aged, Cardiovascular Diseases, Chronic Disease, Double-Blind Method, Female, Follow-Up Studies, Heart Failure, Heterocyclic Compounds, 2-Ring, Hospitalization, Humans, Hypotension, Male, Middle Aged, Pyrimidines, Stroke Volume, Syncope, Incidence, Ventricular Dysfunction, Left
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.